← FDA DRUG APPROVALS

FDA NDA · NDA021774

AMBIEN CR

zolpidem tartrate

Sponsor: COSETTE

APPLICATION
NDA021774
TYPE
NDA
ORIGINAL APPROVAL
2005-09-02
LATEST ACTION
2022-02-23
ROUTE
ORAL
DOSAGE FORM
TABLET, EXTENDED RELEASE
MARKETING STATUS
Prescription

Products

AMBIEN CR · ReferencePrescription
ZOLPIDEM TARTRATE 6.25MG · TABLET, EXTENDED RELEASE · ORAL
AMBIEN CR · ReferencePrescription
ZOLPIDEM TARTRATE 12.5MG · TABLET, EXTENDED RELEASE · ORAL

Approval history

2022-02-23Labeling · Supplement 25 · standardLetterAP
2022-02-23Labeling · Supplement 21 · standardLetterAP
2022-02-23Labeling · Supplement 28 · standardLetterAP
2019-08-18Labeling · Supplement 27 · standardLetterAP
2019-02-06Labeling · Supplement 26 · 901 requiredLabelAP
2018-09-14Labeling · Supplement 23 · standardLetterAP
2017-03-03Labeling · Supplement 19 · standardLabelAP
2016-12-02Labeling · Supplement 18 · standardLabelAP
2016-08-11Labeling · Supplement 17 · standardLetterAP
2014-10-07Labeling · Supplement 16 · standardLabelAP
2013-04-19Labeling · Supplement 15 · standardLetterAP
2013-04-19Labeling · Supplement 13 · standardLabelAP
2010-04-14Labeling · Supplement 10 · unknownLetterAP
2007-12-20Efficacy · Supplement 5 · standardLabelAP
2007-12-20Efficacy · Supplement 3 · unknownLabelAP
2007-12-20Efficacy · Supplement 8 · standardLabelAP
2007-12-20Efficacy · Supplement 4 · standardLetterAP
2007-12-20Labeling · Supplement 7 · standardLabelAP
2005-09-02Type 3 - New Dosage Form · Original · standardLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →